Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114333 · ClinicalTrials.gov registry record · Phase 1
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
A Phase 1 study of Herpes Zoster and Shingles, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT02114333: Completed Phase 1 study of Herpes Zoster and Shingles, sponsored by University of Colorado, Denver.
NCT02114333 is a Phase 1 study of Herpes Zoster and Shingles that has completed, run by University of Colorado, Denver. The registered enrollment target is 160 participants, below the 2,163-participant average among 16 other Herpes Zoster trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02114333, a Phase 1 study of Herpes Zoster and Shingles, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the two vaccines that have been developed to prevent and/or lessen the effects of shingles. One vaccine is live (Zostavax, licensed by FDA) and the other, herpes zoster subunit (HZ/su), contains a piece of the shingles virus (not live) and an ingredient that may enhance the body's immune response to the vaccine, and is currently investigational. The vaccines are being compared to assess their ability to stimulated protection against shingles. The study will provide an opportunity to determine the safety profile of each vaccine in a single trial. The study will also look at the effect of age on the immune response to the two vaccines and on the persistence of these responses.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL HZ/su vaccine
- BIOLOGICAL Zostavax
Study Locations (1)
Colorado
- Pediatric Infectious Diseases and Clinical Trials, Universtiy of Colorado School of Medicine - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-05 |
| Phase | Phase 1 |
What the finished NCT02114333 record still lists
NCT02114333 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 2,163-participant average among 16 other Herpes Zoster trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Herpes Zoster appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02114333 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT02114333 about?
NCT02114333 is a clinical study titled "Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds". This study will compare the two vaccines that have been developed to prevent and/or lessen the effects of shingles. One vaccine is live (Zostavax, licensed by FDA) and the other, herpes zoster subunit (HZ/su), contains a piece of the shingles virus (not live) and an ingredient that may enhance the b...
What is the current status of trial NCT02114333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2014-05. Estimated completion is 2020-05.
What conditions does trial NCT02114333 study?
This clinical trial studies the following conditions: Herpes Zoster, Shingles.
What interventions are being tested in trial NCT02114333?
The interventions under investigation include: Placebo (BIOLOGICAL), HZ/su vaccine (BIOLOGICAL), Zostavax (BIOLOGICAL).
Who is sponsoring clinical trial NCT02114333?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02114333 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02114333's enrollment target sits among peer trials
160 11th of 16 higher than 6 of 16 other Herpes Zoster trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
COMPLETED · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia